It is a given that recent studies on tumor glutamine metabolism have concentrated on the development of GLS1 allosteric inhibitors, to which our research group has contributed several works.[13, 33] These inhibitors exhibit high selectivity and safety and reveal promising antitumor activities in vitro; however, achieving limited progress in vivo and in the clinical setting. This evidence concerns the gene GLS and neoplasm.